Edition:
United States

Krystal Biotech Inc (KRYS.OQ)

KRYS.OQ on NASDAQ Stock Exchange Capital Market

17.00USD
20 Sep 2018
Change (% chg)

$0.48 (+2.91%)
Prev Close
$16.52
Open
$16.58
Day's High
$17.95
Day's Low
$16.58
Volume
3,211
Avg. Vol
10,337
52-wk High
$21.14
52-wk Low
$8.03

Latest Key Developments (Source: Significant Developments)

Krystal Biotechs' Kb105 Receives Rare Pediatric Disease Designation From FDA
Thursday, 23 Aug 2018 08:00am EDT 

Aug 23 (Reuters) - Krystal Biotech Inc ::KRYSTAL BIOTECHS’ KB105 RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA TO TREAT PATIENTS WITH TGM-1-DEFICIENT AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS.KRYSTAL BIOTECH - RPDD MAKES KB105 PROGRAM ELIGIBLE FOR RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER UPON APPROVAL OF KB105 BY FDA.  Full Article

U.S. FDA Grants Fast Track Designation For Krystal Biotech’S Kb103
Thursday, 24 May 2018 08:00am EDT 

May 24 (Reuters) - Krystal Biotech Inc ::U.S. FDA GRANTS FAST TRACK DESIGNATION FOR KRYSTAL BIOTECH’S KB103 FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA.  Full Article

Krystal Submits Investigational New Drug (Ind) Application For KB103
Tuesday, 27 Mar 2018 08:00am EDT 

March 27 (Reuters) - Krystal Biotech Inc ::KRYSTAL SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KB103, TOPICAL GENE THERAPY CANDIDATE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA.KRYSTAL BIOTECH - THERAPEUTIC CANDIDATE FORMULATED INTO A TOPICAL GEL FOR DIRECT APPLICATION ONTO SKIN.  Full Article

Krystal Biotech Reports 2017 Financial Results And Business Progress
Monday, 12 Mar 2018 08:00am EDT 

March 12 (Reuters) - Krystal Biotech Inc ::KRYSTAL BIOTECH REPORTS 2017 FINANCIAL RESULTS AND BUSINESS PROGRESS.  Full Article

Krystal Biotech reports qtrly loss per share $1.26‍​
Monday, 13 Nov 2017 04:01pm EST 

Nov 13 (Reuters) - Krystal Biotech Inc :Krystal Biotech reports that KB103 received clearance from RAC review and announces third quarter 2017 financial results.Krystal Biotech Inc qtrly loss per share $1.26‍​.Krystal Biotech Inc - ‍Currently preparing to file an investigational drug application for KB103 in Q1 of 2018​.  Full Article

Krystal Biotech says KB103 granted orphan drug designation by FDA
Tuesday, 7 Nov 2017 08:00am EST 

Nov 7 (Reuters) - Krystal Biotech Inc :Krystal Biotech’s KB103 granted orphan drug designation by the FDA to treat patients with dystrophic epidermolysis bullosa.Krystal Biotech Inc - on track to file IND for KB103 in Q1 2018​.  Full Article

Krystal Biotech shares open at 5 pct above IPO price
Wednesday, 20 Sep 2017 12:16pm EDT 

Sept 20 (Reuters) - :Krystal Biotech Inc shares open at $10.50 in debut on the NASDAQ versus IPO price of $10.00 per share.  Full Article